VivoSeq
Hematology

Primary Systemic Amyloidosis

16

Pipeline Programs↗

0

Active Trials↗

9

Companies Involved↗

Primary Systemic Amyloidosis is an emerging landscape with 16 programs across 9 companies. The most active players are Gynecologic Oncology Group, Eastern Cooperative Oncology Group, Bristol-Myers Squibb. 2 therapies are approved with 2 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

42/100

Pipeline Velocity

0/100

Mech. Concentration

13/100

Completion Rate

88/100

Attrition Rate

12/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

G

Gynecologic Oncology Group

1 program

Phase 1E

Eastern Cooperative Oncology Group

2 programs

Phase 2Bristol-Myers Squibb logo

Bristol-Myers Squibb

2 programs

Phase 2I

Immunex

1 program

Phase 2K

Karuna Therapeutics, Inc., a Bristol Myers Squibb company

1 program

Phase 2Akero Therapeutics logo

Akero Therapeutics

1 program

Phase 2

Pipeline

Programs by Phase

Analysis

Modality Breakdown

80%

Small molecule

12 of 15 classified programs — the dominant modality here.

20%ALL OTHERSProtein / enzyme320%

Small molecule leads; the ring shows all 15 classified programs, each share of the total. Modality classified for 100% of 16 pipeline programs.

Analysis

Trial Status

17

clinical trials

Completed15 · 88%
Terminated2 · 12%

Clinical Trials

Trial Activity

17 trials

S0115, High-Dose Melphalan and Autologous Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma or Primary Systemic Amyloidosis
Completed·SWOG Cancer Research Network·Phase 2·NCT00064337·104 enrolled
S9628 Dexamethasone Plus Interferon Alfa in Treating Patients With Primary Systemic Amyloidosis
Completed·SWOG Cancer Research Network·Phase 2·NCT00002849·93 enrolled
Lendexal in Patients With Primary Systemic Amyloidosis (AL) Newly Diagnosed
Completed·PPETHEMA Foundation·Phase 2·NCT01194791·30 enrolled
Low-Dose Melphalan and Dexamethasone Compared With High-Dose Melphalan Followed By Autologous Stem Cell Transplant in Treating Patients With Primary Systemic Amyloidosis
Completed·MMayo Clinic·Phase 3·NCT00477971·89 enrolled
Melphalan, Thalidomide, and Dexamethasone in Treating Patients With Newly Diagnosed, Previously Untreated Primary Systemic Amyloidosis
Completed·MMemorial Sloan Kettering Cancer Center·Phase 2·NCT00089167
Study of Bortezomib +HSCT in Primary Systemic Amyloidosis (AL)
Completed·—·N/A·NCT01273844·21 enrolled
CC-5013 With or Without Dexamethasone in Treating Patients With Primary Systemic Amyloidosis
Completed·—·Phase 2·NCT00091260·82 enrolled
Melphalan, Bortezomib, and Stem Cell Transplant in Treating Patients With Primary Systemic Amyloidosis
Completed·—·Phase 2·NCT00790647·10 enrolled
Phase II Trial of Enbrel in Patients With Primary Systemic Amyloidosis
Completed·TThe Cleveland Clinic·Phase 2·NCT00224393·60 enrolled
Melphalan, Lenalidomide, and Dexamethasone in Treating Patients With Primary Systemic Amyloidosis
Completed·—·Phase 2·NCT00679367·16 enrolled
Efficacy of CC-5013 (Revlimid or Lenalidomide) in Patients With Primary Systemic Amyloidosis
Completed·MMayo Clinic·Phase 2·NCT00166413·38 enrolled
High-Dose Melphalan Plus Peripheral Stem Cell Transplantation in Treating Patients With Primary Systemic Amyloidosis
Completed·EEastern Cooperative Oncology Group·Phase 2·NCT00003353
Chemotherapy Plus Peripheral Stem Cell Transplant in Treating Patients Who Have Multiple Myeloma or Primary Systemic Amyloidosis
Completed·HHerbert Irving Comprehensive Cancer Center·Phase 2·NCT00007995·75 enrolled
Lenalidomide, Cyclophosphamide, and Dexamethasone in Treating Patients With Primary Systemic Amyloidosis
Completed·MMayo Clinic·Phase 2·NCT00564889·35 enrolled
4'-Iodo-4'-Deoxydoxorubicin in Treating Patients With Primary Systemic Amyloidosis
Completed·National Cancer Institute (NCI)·Phase 2·NCT00003853·45 enrolled
Page 1 of 2

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)